Shield Therapeutics will get $7.9 million when its Chinese partner applies to sell a drug.

Shield Therapeutics is set to receive a significant boost, a $7.9 million milestone payment, from its Chinese partner, Beijing Aosaikang Pharmaceutical Co.

Ltd (ASK).

This payment is triggered by ASK's plan to submit a marketing authorization application for ACCRUFeR, an iron deficiency drug, in China.

The filing with the China National Medical Products Administration (NMPA) is anticipated in the first quarter of 2026.

Importantly, this application will include pediatric data from Shield's Phase 3 clinical trials, which previously helped secure US FDA approval for children aged 10 and older.

The $7.9 million is expected by January 31, 2026.

Shield Therapeutics intends to use these funds to settle and terminate its AOP Milestone Monetisation Agreement.

This strategic move aims to simplify Shield's capital structure and improve its financial health.

The original 2020 licensing deal covered ACCRUFeR's development and commercialization across China, Hong Kong, Macau, and Taiwan.

The revised agreement also outlines potential additional milestones and royalties up to 10% on net sales, replacing an earlier, larger milestone.

ACCRUFeR remains an innovative treatment with patent protection until the mid-2030s.